ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

fluciclovine F-18

Also written as “18F fluciclovine”, “fluciclovine (18F)” and “18F-fluciclovine PET CT”.

Its studies are mostly in Prostatic Neoplasms · Brain Neoplasms, led by 2 companies.

Drug pageFluciclovine F-18: every studyAll 37 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 22, 20265 company-led studies, 1 open or runningNext primary completion: Dec 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Braccoits history only41 open or runningphase 4since Apr 22, 2026Jan 15, 2016Dec 31, 2027phase 4 · NCT07569926
GE Healthcare10 open or runningphase 2since Aug 5, 2010Aug 5, 2010none ahead

Also a collaborator on its studies: Precision For Medicine, IND 2 Results and Syne Qua Non.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GE Healthcare only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 5, 2010First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT01176513 · 25 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study GE Healthcare leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01176513Prostatic Neoplasms · United States2TerminatedMar 201225

How it is read

Names in the registry

  • “18F fluciclovine”, 2 entries
  • “fluciclovine (18F)”, 1 entry
  • “18F-fluciclovine PET CT”, 1 entry
  • “GE-148 (18F)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.